1. Smyth, RL, Openshaw, PJ. Bronchiolitis. Lancet 2006; 368: 312–322.
2. Vogel, A, Lennon, D, Harding, J. Trends in bronchiolitis admissions in New Zealand. Proceedings of the Paediatric Society of New Zealand 2000, PO2.
3. Shay, DK, et al. Bronchiolitis-associated hospitalizations among US children, 1980–1996. Journal of the American Medical Association 1999; 282: 1440–1446.
4. Simoes, EA, Carbonell-Estrany, X. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatric Infectious Diseases Journal 2003; 22: S13–20.
5. NZ Child and Youth Epidemiology Service. The health of children and young people in the (sample) region. NZ Child and Youth Epidemiology Service, Auckland, 2005, pp. 52–55.
6. Welliver, RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. Journal of Pediatrics 2003; 143: S112–117.
7. Vogel, AM, et al. Variations in bronchiolitis management between five New Zealand hospitals: can we do better? Journal of Paediatrics and Child Health 2003; 39: 40–45.
8. Barry, W, et al. Ribavirin aerosol for acute bronchiolitis. Archives of Diseases in Childhood 1986; 61: 593–597.
9. Dawson, K, et al. The management of acute bronchiolitis. Thoracic Society of Australia and New Zealand. Journal of Paediatrics and Child Health 1993; 29: 335–337.
10. Statistics New Zealand. Information Guide 1996 Census of Populations and Dwellings, 1997, p. 33.
11. McIntosh, ED, De Silva, LM, Oates, RK. Clinical severity of respiratory syncytial virus group A and B infection in Sydney, Australia. Pediatric Infectious Diseases Journal 1993; 12: 815–819.
13. Matheson, JW, et al. Distinct patterns of evolution between respiratory syncytial virus subgroups A and B from New Zealand isolates collected over thirty-seven years. Journal of Medical Virology 2006; 78: 1354–1364.
14. Rothman, KJ, Greenland, S. Modern Epidemiology. Philadelphia: Lippincott-Raven, 1998.
16. Holberg, CJ, et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. American Journal of Epidemiology 1991; 133: 1135–1151.
17. Whitehall, JS, et al. High rate of indigenous bronchiolitis and palivuzumab. Journal of Paediatrics and Child Health 2001; 37: 416–417.
18. Reeve, CA, et al. Predicting respiratory syncytial virus hospitalization in Australian children. Journal of Paediatrics and Child Health 2006; 42: 248–252.
19. Holman, RC, et al. Respiratory syncytial virus hospitalizations among American Indian and Alaska Native infants and the general United States infant population. Pediatrics 2004; 114: e437–444.
20. Bulkow, LR, et al. Risk factors for severe respiratory syncytial virus infection among Alaska native children. Pediatrics 2002; 109: 210–216.
21. Sangare, L, Curtis, MP, Ahmad, S. Hospitalization for respiratory syncytial virus among California infants: disparities related to race, insurance, and geography. Journal of Pediatrics 2006; 149: 373–377.
22. Salmond, C, Crampton, P. NZDEP96 – what does it measure? Social Policy Journal of New Zealand 2001; 17: 82–100.
23. Salmond, C, et al. NZiDep: a New Zealand index of socioeconomic deprivation for individuals. Social Science & Medicine 2006; 62: 1474–1485.
24. Lofgren, J, et al. Association between surfactant protein A gene locus and severe respiratory syncytial virus infection in infants. Journal of Infectious Diseases 2002; 185: 283–289.
25. Puthothu, B, et al. Association between severe respiratory syncytial virus infection and IL13/IL4 haplotypes. Journal of Infectious Diseases 2006; 193: 438–441.
26. Janssen, R, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. Journal of Infectious Diseases 2007; 196: 826–834.
27. Wilson, J, et al. Genetic variation at the IL10 gene locus is associated with severity of respiratory syncytial virus bronchiolitis. Journal of Infectious Diseases 2005; 191: 1705–1709.
28. Amanatidou, V, et al. T280M variation of the CX3C receptor gene is associated with increased risk for severe respiratory syncytial virus bronchiolitis. Pediatric Infectious Diseases Journal 2006; 25: 410–414.
29. Pearce, N, et al. Genetics, race, ethnicity, and health. British Medical Journal 2004; 328: 1070–1072.
30. Singleton, R, et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatric Pulmonology 2000; 29: 182–187.
31. Chang, AB, et al. Bronchiectasis in indigenous children in remote Australian communities. Medical Journal of Australia 2002; 177: 200–204.
32. Grant, CC, et al. Hospitalisation for pneumonia in children in Auckland, New Zealand. Journal of Paediatrics and Child Health 1998; 34: 355–359.
33. Pattemore, PK, et al. Asthma prevalence in European, Maori, and Pacific children in New Zealand: ISAAC study. Pediatric Pulmonology 2004; 37: 433–442.
34. Twiss, J, et al. New Zealand national incidence of bronchiectasis ‘too high’ for a developed country. Archives of Diseases of Children 2005; 90: 737–740.
35. Ellison-Loschmann, L, Pearce, N. Improving access to health care among New Zealand's Maori population. American Journal of Public Health 2006; 96: 612–617.
36. Gavin, R, Anderson, B, Percival, T. Management of severe bronchiolitis: indications for ventilator support. New Zealand Medical Journal 1996; 109: 137–139.
37. Sigurs, N, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. American Journal of Respiratory and Critical Care Medicine 2005; 171: 137–141.
38. Bont, L, et al. Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. Pediatric Infectious Disease Journal 2004; 23: 414–417.
39. Singleton, RJ, et al. Sequelae of severe respiratory syncytial virus infection in infancy and early childhood among Alaska Native children. Pediatrics 2003; 112: 285–290.